Company targets Traumatic Brain Injury, ALS, Blood Sepsis and other debilitating diseases affecting millions of Americans
EL PASO, Texas--(BUSINESS WIRE)--
Premier Biomedical, Inc. (OTCBB: “BIEI”) a biopharmaceutical company focused on developing and commercializing innovative treatment therapies for cancer, traumatic brain injury, Alzheimer’s disease, and other afflictions announced today that the investment research company, OxBridge Research, has concluded and published its in-depth study of Premier Biomedical, Inc.
The analyst noted in his report that in addition to the company developing cures for “ Cancer, Traumatic Brain Injury, Alzheimer’s, Multiple Sclerosis, ALS and Blood Sepsis – collectively over a $700 billion market opportunity”, the company has established two outstanding research partnerships with the University of Texas, El Paso (UTEP) and the Department of Defense, and is making preparations to initiate two clinical trials (a trial for Feldetrex and a trial of the Sequential Dialysis Technique).
The complete 28 page report is now available for download from the company's website (http://www.premierbiomedical.com/oxbridge-research-investment-summary/) as well as from OxBridge Research’s site, www.oxbridgeresearch.com
About Premier Biomedical, Inc.
Premier Biomedical, Inc. is a research-based company that intends to discover and develop medical treatments for a wide range of diseases in humans, in collaboration with the University of Texas at El Paso and US Department of Defense, initially targeting the treatment of Alzheimer's disease, Traumatic Brain Injury, and Cancer. Premier has licensed the technology behind multiple provisional patents in the United States and a PCT Europe National Patent in the areas of Cancer, Sepsis, and Multiple Sclerosis. Founded in 2010, Premier has partnered with the Department of Defense with Center of Expertise at the William Beaumont Army Medical Center and the University of Texas at El Paso (UTEP). The company's R&D efforts are centered in El Paso, TX and their business offices are in Western Pennsylvania. The Company's common stock trades on the fully reporting Over-The-Counter Bulletin Board under the ticker symbol "BIEI." http://www.premierbiomedical
Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Premier Biomedical, Inc. cautions that statements made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates and assumptions made by management. Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.
Forward-looking statements:- The Company's actual results, performance or achievements could differ materially from those expressed in, or implied by, these forward-looking statements, including those described in the Company's Financial Statements, Management Discussion and Analysis and Material Change Reports filed with the with the United States Securities and Exchange Commission and available at www.sec.gov.
This profile/research report/email letter/blog/posting in forums/social-media/t/f does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities of the Company may or may not have been registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available. We do not accept responsibility for the adequacy or accuracy of this release.
Disclosure/Disclaimer:- OxBridge Research and its affiliates/partners publish sponsored research reports, advertorials and corporate profiles on its portal and several other websites/blogs, including this website/blog, owned and operated by OxBridge and/or its affiliates/partners. OxBridge Research is not a Broker Dealer or a Registered Financial Adviser in any jurisdiction, whatsoever. All the information published on its website(s) and/or distributed to its members via various electronic means is for general awareness and entertainment purpose only. OxBridge urges investors to do their own due diligence and consult with their financial adviser prior to making any investment decision. We are expecting a payment of up to five thousand dollars in compensation from the company/a third party/shareholder. We receive compensation from companies for providing various IR services, including publication, advertisement, and social media awareness, therefore our views/opinion are inherently biased. Please read the full disclosure/disclaimer; if you need assistance contact Editor@OxBridgeResearch.com
Contact:
No comments:
Post a Comment